BMY Analysts Split as Q3 Print Approaches

Bristol-Myers Squibb reports Q3 earnings on October 29 with the analyst community more divided than its stable share price suggests.

The clearest tension heading into the print is in analyst opinion, not positioning. The direction of travel over the past three weeks has been largely negative. Wells Fargo cut its target to $60 from $65 on October 13, keeping an Equal-Weight rating. Cantor Fitzgerald trimmed to $53 from $59 on October 8. Most notable was Leerink Partners, which downgraded to Market Perform from Outperform and slashed its target to $59 from $73 on October 5. Against that, Morgan Stanley, which carries an Underweight rating, nudged its target to $41 from $40, a marginal move that does little to shift the bearish framing. The consensus mean target of $65.41 sits modestly above the current $61.48, implying limited perceived upside at the Street level, while a minority of bulls remain considerably more constructive: Piper Sandler carries an $82 Overweight target and JP Morgan an Overweight at $73.

The bull case rests on Opdivo, Qvantig, and Eliquis, where management has guided for 10 to 15% growth in the latter for the full year. Upcoming clinical readouts and potential label expansions give the optimists a further catalyst runway. The bears counter with heavy US revenue concentration (around 70% of total sales), which leaves the company exposed to domestic pricing and policy risk, alongside the ongoing genericisation headwind from Revlimid and the pace at which newer assets can compensate. The two camps are essentially debating transition speed: how fast the growth portfolio offsets the legacy drag.

Short interest offers no meaningful signal here. At 2.2% of the free float, it has edged down roughly 1% over the past week and drifted modestly higher over the past month, with none of those moves large enough to suggest a change in conviction. The borrow market is similarly unconstrained: availability is essentially unlimited, and cost to borrow at 0.46% is near its lowest of the year despite a near-29% jump over the past week in percentage terms. That weekly move sounds dramatic but it brings the rate only to a level still consistent with easy, cheap borrowing. There is no squeeze pressure from the lending market.

Retail attention is elevated. Wikipedia page views for the company are running more than two standard deviations above their 90-day average, suggesting BMY is drawing more public interest than usual in the days before the release. The Medicaid drug data from the Centers for Medicare and Medicaid Services adds context: reimbursed dollars were down 26% year on year in Q1 2026, and prescription volumes fell 11% over the same period. Neither dataset has been measured to lead BMS's reported financials, so neither can be called predictive, but the reimbursement trend is a data point bears will note.

The print will test whether Opdivo and Eliquis growth is running fast enough to justify the multiple for investors who stayed long through a stock down about 1.2% over the past month, while peers posted median weekly gains above 2%.